Eli Lilly (LLY) Slid on Rare Revenue Miss in its 3Q Update
RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...
Eli Lilly’s three-year Ebglyss study leaves 50% of AD patients with clear skin
The three-year study of Ebglyss saw an additional 83% of dermatitis patients achieving ‘almost clear’ skin using the single ...
Dexcom Appoints Renée Galá to Board of Directors
(NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March 6, 2025. Ms. Galá is an accomplished executive with ...
pharmaphorum44m
Novo Nordisk's CagriSema data disappoints investors again
Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...